StockpollyBeta
Get App
Popularity #677
NVAX · NASDAQ · Biotechnology

Novavax (NVAX)

Builds protein vaccines and Matrix-M partnerships around Nuvaxovid and R21/Matrix-M.

$10.90
After hours+0.06 (+0.58%)
At close$10.84(+4.08%)

In millions of USD, except per-share figures

In millionsQ3 FY23Sep 2023Q4 FY23Dec 2023Q1 FY24Mar 2024Q2 FY24Jun 2024Q3 FY24Sep 2024Q4 FY24Dec 2024Q1 FY25Mar 2025Q2 FY25Jun 2025Q3 FY25Sep 2025Q4 FY25Dec 2025Q1 FY26Mar 2026Q2 FY26Jun 2026
Revenue222919441585886672397014714057
Cost of revenue9914949466137141421253114
Gross profit−771424536924526532254912210942
4932618420815818313711922710112497
Research & development1061659310787104897898749571
Selling, general & administrative10715582101717848413227290
Other expenses−1656900001970027
Operating income−126−184−139161−134−131516106−17821−15−55
−67−74125742−25−373
Interest expense3444486656−56
Other non-operating income3−112−8−16−65−10−720−3−12−9
Income before tax−131−177−145165−122−74520107−20318−9−52
Income tax expense−1222−1711−1012
Net income from continuing operations−131−178−148162−121−81519107−20218−9−53
Net income−131−178−148162−121−81519107−20218−9−53
EPS, basic−$1.26−$1.44−$1.05$1.11−$0.76−$0.51$3.22$0.66−$1.25$0.11−$0.06−$0.32
EPS, diluted−$1.26−$1.44−$1.05$0.99−$0.76−$0.51$2.93$0.60−$1.25$0.11−$0.06−$0.32
Weighted average shares, basic103124140148160160161162162162163165
Weighted average shares, diluted103124140166160160178177162173163165
EBITDA−117−162−129180−105−53534121−19129−1−40
Depreciation & amortization111112111313887536
EBIT−129−173−141169−118−66526113−19824−4−46